Takeaway

• A single subcutaneous injection of a short interfering RNA (siRNA), SLN360, was well tolerated and resulted in significant reductions in plasma lipoprotein(a) (Lp[a]) levels in a small phase 1 trial.

Why this matters

• Lp(a) is a key risk factor for atherothrombotic cardiovascular disease (CVD) and aortic stenosis, which has...